Pharmacokinetics of amikacin in plasma of healthy goats after intravenous injection once daily for three days

Sania Naseem, Mudasir Sultana, Rajinder Raina, Nrip Kishore Pankaj, Pawan Kumar Verma, Nasir Ahmad Nasir, Azad Ahmad Ahanger, Shafiqur Rahman, Shahid Prawez
2011 Korean Journal of Veterinary Research  
Amikacin is a semisynthetic derivative of kanamycin and primarily active against aerobic Gramnegative-pathogens with limited activity against Gram-positive bacteria. Meager study was reported on pharmacokinetic data on multi-days administration of amikacin. Hence, pharmacokinetics study was done in five clinically healthy goats (n = 5), after intravenous bolus injection of amikacin sulfate at the dose rate of 10 mg/kg body weight daily for three consecutive days. The amikacin concentrations in
more » ... concentrations in plasma and pharmacokinetics-parameters were analyzed by using microbiological assay technique and noncompartmental open-model, respectively. The mean peak plasma concentrations (Mean ± SD) of amikacin at time zero (Cp 0 ) was 114.19 ± 20.78 and 128.67 ± 14.37 µg/mL, on day 1st and 3rd, respectively. The mean elimination half-life (t = 0.07 ± 0.02 and 0.06 ± 0.01 L/ and Vdss = 0.10 ± 0.03 and 0.11 ± 0.05 L/kg, respectively. No-significant difference was noted in both drug-plasma concentration and pharmacokinetics-parameters, respectively. Amikacin concentration in plasma was found higher up-to 4 h and 6 h onward on down-ward trends favour to reduce toxicity. Which also support the pharmacokineticpharmacodynamic way of dosing of aminoglycosides and hence, amikacin may be administered 10 mg/ kg intravenously daily to treat principally Gram-negative pathogens and limitedly Gram-positive-pathogens.
doi:10.14405/kjvr.2011.51.4.253 fatcat:semz7jpb5rbprapox2pfaxxbwa